Century Therapeutics, Inc.
Company Stats
- Market Cap
- $309.6M
- as of Sep 30, 2026
- Shares Outstanding
- 181.1M
- Free Float
- 85.4%
Income Statement
- Revenue
- $109.2M
- Operating Income
- -$17.3M
- Net Income
- -$9.6M
- EBITDA
- -$4.2M
- Non-cash Impairment
- $6.8M
- Revenue Growth, 3Y
- 175.9%
- FCF Margin, 3Y Avg
- -2112.4%
- FCF Margin, Worst Year
- -4567.5%
Cash Flow
- Free Cash Flow
- -$104.7M
- FCF Yield
- -33.8%
- Owner FCF Yield
- -36.0%
Balance Sheet
- Cash & Equivalents
- $61.9M
Returns & Capital
- SBC, 3Y Avg
- $11.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $109.2M | -$104.7M | -95.9% |
| FY2024 | $6.6M | -$110.3M | -1673.8% |
| FY2023 | $2.2M | -$102.1M | -4567.5% |
| FY2022 | $5.2M | -$16.6M | -318.4% |
| FY2021 | — | -$134.0M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges